

December 6, 2023

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, Representative Director, CEO
	(Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division
	(TEL: 81-3-6838-2803)

Notice Regarding Head Office Relocation

TOHO HOLDINGS CO., LTD. is pleased to announce that TOHO HOLDINGS and its subsidiaries will relocate head offices as below.

1. Relocation site

Tokyo Midtown Yaesu, Yaesu Central Tower 9F and part of 8F
2-2-1, Yaesu, Chuo-ku, Tokyo 104-0028 Japan

2. Relocation Date

December 11, 2023 (from Marunouchi Office Divisions)
December 18, 2023 (from Daizawa Office Divisions)

3. Companies to be relocated

TOHO HOLDINGS CO., LTD., TOHO PHARMACEUTICAL CO., LTD., PharmaCluster Co.,Ltd, PHARMA MIRAI INC., KYOSOMIRAI PHARMA CO., LTD., Orphan Trust Japan Co., Ltd., eKenkoshop Corporation

4. Reason for relocation

To improve management efficiency, prompt decision making, vitalize the workplace through the creation of communication, improve the quality of communication with business partners and to reduce fixed costs by consolidating and relocating the functions of the head office, which are distributed in Daizawa, Setagaya-ku and Marunouchi, Chiyoda-ku.

5. Impact on performance

Expenses associated with this relocation have been factored into the full-year forecast for the fiscal year ending March 2024.

6. Other

The Company's head office location under the Articles of Incorporation is unchanged from Setagaya-ku, Tokyo.